RealMedVision

Pulmonary Hypertension — High Blood Pressure in the Lungs

WHO Classification, Symptoms, Causes, Types, Diagnosis, Treatment & Prevention

A Patient-Friendly Guide by RealMedVision

Why does this matter to you? Pulmonary hypertension (PH) is a condition where the blood pressure inside your lung arteries becomes dangerously high. It silently damages your heart and lungs together — and most people find out only after months of unexplained breathlessness. The WHO has grouped this disease into five categories to help doctors find the right treatment faster. This article explains all of that — in plain language.

Table of Contents

What You Will Learn
What Is Pulmonary Hypertension?
How Does It Develop Inside the Body? (Pathophysiology)
WHO Classification — Groups 1 to 5
Quick Reference Table
Symptoms of Pulmonary Hypertension
How Is It Diagnosed?
Treatment Options
Prognosis — What to Expect
Prevention & When to See a Doctor
Frequently Asked Questions
Trusted Medical References

What You Will Learn

By the end of this article, you will understand:

What pulmonary hypertension actually is — in simple language
How this disease develops inside your body — step by step (Pathophysiology)
The WHO classification system — Groups 1 to 5 explained clearly
Early symptoms that are easy to miss
The main causes and risk factors for each group
How doctors diagnose pulmonary hypertension — and which tests matter
Treatment options from medicines to surgery
Lifestyle changes that genuinely help
Prognosis — what to realistically expect
When to see a doctor immediately

What Is Pulmonary Hypertension?

When we talk about blood pressure, most people think of the number measured on the arm. But your lungs have their own blood supply — a separate circuit of blood vessels called the pulmonary circulation. When the pressure in these vessels rises beyond normal limits, it is called pulmonary hypertension (PH).

A normal pulmonary artery pressure at rest is around 14 mmHg. The World Health Organization and the European Society of Cardiology define pulmonary hypertension as a mean pulmonary artery pressure of 20 mmHg or higher — measured through a procedure called right heart catheterization. This updated threshold was established at the 2018 World Symposium on Pulmonary Hypertension.

As the pressure in the lung arteries rises, the right side of the heart — which pumps blood to the lungs — has to work harder and harder. Over time, this side of the heart enlarges, weakens, and eventually fails. This is why pulmonary hypertension, if left untreated, is a life-threatening condition. It is important to understand that this is different from the regular blood pressure measured on your arm — pulmonary hypertension specifically affects the lung circulation.

According to the Cleveland Clinic, pulmonary hypertension affects an estimated 1 percent of the global population. The Mayo Clinic further notes that this number rises sharply among elderly individuals and those living with underlying lung or heart disease.

How Does Pulmonary Hypertension Develop Inside the Body?

To understand this disease, imagine your lung blood vessels as wide, soft pipes. Normally, blood flows through them easily — relaxed and without resistance. But in pulmonary hypertension (PH), these pipes start to narrow, stiffen, and sometimes get blocked. The heart then has to push blood with much greater force just to get it through. This is the core of the disease.

Here is how it happens, step by step:

Step 1 — The blood vessel walls begin to change. The inner lining of the pulmonary arteries — called the endothelium — gets damaged or disturbed. This can happen due to a genetic mutation, a virus, low oxygen levels, a blood clot, or increased pressure from the heart. Once this lining is disturbed, it stops producing a chemical called nitric oxide, which normally keeps blood vessels relaxed and open.

Step 2 — The vessels start to tighten. Without enough nitric oxide, the vessel walls go into spasm — they squeeze inward. At the same time, another chemical called endothelin increases. Endothelin is a powerful constrictor — it makes vessels narrow even further. According to Braunwald's Heart Disease, this imbalance between vessel-relaxing and vessel-tightening chemicals is one of the earliest and most important events in pulmonary hypertension.

Step 3 — The vessel walls thicken permanently. Over weeks and months, the muscle layer inside the artery walls grows thicker. The inner lining also overgrows. Small clots may form inside narrow vessels. What started as a spasm becomes a permanent, structural narrowing. This stage is called pulmonary vascular remodeling — and once it is established, it cannot fully reverse on its own.

Step 4 — The right side of the heart struggles. The right ventricle — the chamber that pumps blood into the lungs — now faces much higher resistance. It has to work far harder than it was designed to. At first, it compensates by getting bigger and stronger. But over time, this compensation fails. The right ventricle enlarges, weakens, and begins to fail. According to Hurst's The Heart, right heart failure is the final common pathway in all forms of untreated pulmonary hypertension — and the most common cause of death in these patients. The higher the pulmonary artery pressure, the faster this deterioration occurs.

Step 5 — The whole body feels the effect. When the right heart fails, less blood reaches the lungs to pick up oxygen. Less oxygenated blood then reaches the rest of the body. This is why patients feel breathless, dizzy, and exhausted — their muscles and organs are simply not getting enough oxygen. Fluid starts to back up into the legs and abdomen. The cycle worsens if left untreated.

Key point to remember: The earlier pulmonary hypertension is caught — before permanent vessel remodeling sets in — the more effectively treatment can work. This is why recognizing symptoms early matters so much.

WHO Classification of Pulmonary Hypertension — Groups 1 to 5

Not all pulmonary hypertension (PH) is the same. The pressure can rise due to completely different reasons — some come from the lung blood vessels themselves, others from the heart, the lungs, blood clots, or other diseases. Because the cause determines the treatment, the World Health Organization developed a classification system that divides pulmonary hypertension into five groups.

This classification — first proposed in 1998 and revised at successive world symposia — is now the global standard used by cardiologists and pulmonologists everywhere, including at AIIMS India and leading international cardiac centers.

ai

Group 1Pulmonary Arterial Hypertension (PAH)

This is the most studied and most serious group. The problem here is directly inside the small arteries of the lungs — their walls thicken, they narrow, and blood cannot flow through easily. This is not caused by heart disease or lung disease from outside. It is a disease of the pulmonary vessels themselves. If left untreated, pulmonary arterial hypertension almost always leads to right heart failure.

Causes include: idiopathic (no known cause), inherited genetic mutations, connective tissue diseases like scleroderma, HIV infection, certain drugs like appetite suppressants, portal hypertension, and congenital heart defects. Research from Johns Hopkins Medicine has shown that women are diagnosed with PAH three times more often than men, typically between ages 30 and 50.

Group 2PH Due to Left Heart Disease

This is the most common group overall. When the left side of the heart is not working properly — due to heart failure, thickening of the heart walls, or leaky or narrowed valves — pressure backs up through the lungs. The lungs are caught in the middle. The pulmonary pressure rises as a result of the heart problem, not the lungs themselves.

Treating the underlying heart condition is the priority here. According to MedlinePlus (NIH) and Braunwald's Heart Disease — the standard cardiology reference textbook — managing left heart failure aggressively can significantly reduce pulmonary pressures in Group 2.

Group 3PH Due to Lung Disease or Hypoxia

Chronic lung diseases — particularly COPD (chronic obstructive pulmonary disease), pulmonary fibrosis, sleep apnea, and long-term exposure to low oxygen at high altitudes — can cause pulmonary hypertension. When lungs are damaged or oxygen levels are chronically low, blood vessels in the lungs constrict in response, raising pressure over time.

The Indian Council of Medical Research (ICMR) has noted that in India, Group 3 pulmonary hypertension is significantly under-recognized, particularly in patients with untreated obstructive sleep apnea and advanced COPD.

Group 4Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

This group occurs when old blood clots — usually from a past pulmonary embolism — do not dissolve completely. They scar and block the pulmonary arteries permanently, raising pressure. What makes Group 4 particularly important is that it is potentially curable. A surgical procedure called pulmonary endarterectomy can physically remove the clot material from the arteries, often dramatically improving or completely resolving pulmonary hypertension.

Dr. William Auger at UC San Diego — one of the world's leading centers for CTEPH surgery — has emphasized that every patient with unexplained pulmonary hypertension should be screened for CTEPH, because missing this diagnosis means missing a cure.

Group 5PH with Unclear or Multifactorial Mechanisms

This group is a collection of conditions that raise pulmonary pressure through complex or incompletely understood mechanisms. It includes blood disorders like sickle cell disease, systemic diseases like sarcoidosis, metabolic disorders, and kidney disease. Treatment in Group 5 focuses on managing the underlying condition causing the pulmonary hypertension.

Quick Reference — WHO PH Classification at a Glance

WHO Group	Main Category	Key Cause	Curable?
Group 1	PAH	Vessel wall disease, genetic, HIV, drugs	Manageable, not curable
Group 2	Left heart disease	Heart failure, valve disease	Treat heart condition
Group 3	Lung disease / Hypoxia	COPD, fibrosis, sleep apnea	Manage lung condition
Group 4	Blood clots (CTEPH)	Old pulmonary embolism	Often yes — surgery
Group 5	Mixed / unclear	Sickle cell, sarcoidosis, metabolic	Treat underlying disease

Symptoms of Pulmonary Hypertension

The most frustrating thing about pulmonary hypertension (PH) is how slowly and quietly it develops. The Mayo Clinic describes this disease as one of the most under-diagnosed cardiovascular conditions because its early symptoms overlap so closely with common complaints like fatigue and being out of shape. Understanding pulmonary hypertension symptoms early is the single most important step toward getting the right diagnosis in time.

Early symptoms to watch for:

Breathlessness during activities you used to handle easily
Unusual fatigue — tired even after light effort
Dizziness or fainting, especially during physical activity
A dry, persistent cough
Swelling in the ankles and legs, worsening toward evening
Bluish color of the lips or fingertips (cyanosis) — a more advanced sign
Chest discomfort or chest tightness — especially during exertion

Seek immediate medical attention if you experience: sudden severe breathlessness, chest pain similar to a heart attack, fainting during exertion, or a rapid worsening of leg swelling. These require same-day evaluation at a cardiac center. In some cases, these symptoms can also overlap with early signs of a stroke — do not delay.

How Is Pulmonary Hypertension Diagnosed?

Diagnosis requires a step-by-step process because pulmonary hypertension diagnosis can be easily missed — it is often confused with asthma, general heart failure, or simply deconditioning. According to AIIMS India cardiology protocols and the Cleveland Clinic, a structured investigation approach is essential before any treatment decision is made. Early diagnosis — before right heart failure sets in — dramatically improves outcomes.

Echocardiogram — the first-line test. An ultrasound of the heart estimates pulmonary artery pressure without any needles. It also shows right heart size and function. According to Hurst's The Heart — a major cardiology reference — an echo showing a tricuspid regurgitation velocity above 2.8 m/s is a significant indicator for further investigation of pulmonary hypertension. You can read more about what a 2D Echo test involves and its normal report values in our detailed guide.

Right Heart Catheterization — the gold standard test. A thin tube is guided through a vein into the right side of the heart and pulmonary arteries to directly measure pressure. No other test gives this accuracy. According to the Mayo Clinic, this procedure is required before starting any targeted therapy for Group 1 PAH.

ECG — can show right heart strain patterns. According to Rapid Interpretation of EKGs by Dubin, right axis deviation and right ventricular hypertrophy pattern commonly appear in advanced pulmonary hypertension. For a complete understanding of how an ECG test is done and what results mean, refer to our full ECG guide.

CT Pulmonary Angiography — essential for diagnosing Group 4 (CTEPH) by showing clots in the pulmonary arteries. According to MedlinePlus (NIH), chest X-ray, pulmonary function tests, ventilation-perfusion scan, and blood tests complete the diagnostic workup.

Treatment of Pulmonary Hypertension

Treatment depends entirely on which WHO group the patient falls into. This is why correct classification matters so much — the wrong treatment for the wrong group can be ineffective or even harmful. A key marker doctors monitor during treatment of pulmonary hypertension (PH) is the ejection fraction (EF) — which tells us how well the heart is pumping. Pulmonary hypertension can also trigger atrial fibrillation, a dangerous irregular heart rhythm that requires separate management.

General Treatments (All Groups)

Diuretics to reduce fluid buildup, oxygen therapy when blood oxygen levels are low, anticoagulants in certain patients, and supervised cardiac rehabilitation form the backbone of general management. According to MedlinePlus (NIH), physical activity should be encouraged — but carefully supervised — in all PH patients.

Targeted Therapies for Group 1 PAH

Pulmonary hypertension treatment for Group 1 — also called pulmonary arterial hypertension — has the most options available. Three drug pathways are now targeted: the endothelin pathway (bosentan, ambrisentan), the nitric oxide-PDE5 pathway (sildenafil, tadalafil), and the prostacyclin pathway (epoprostenol, iloprost). Dr. Vallerie McLaughlin at the University of Michigan — a global leader in pulmonary hypertension — has shown in research that combination therapy using two or three of these pathways simultaneously produces better outcomes than single-drug treatment.

Surgical Treatment for Group 4

Pulmonary endarterectomy (PEA) — surgery to remove chronic clots — is the treatment of choice for eligible Group 4 patients and can be curative. For those who cannot undergo surgery, balloon pulmonary angioplasty and a newer drug riociguat have shown significant benefit, according to research published in collaboration with Johns Hopkins Medicine and the International Society for Heart and Lung Transplantation.

Lifestyle changes that genuinely help: Low-sodium diet to reduce fluid retention. Avoid high altitudes. Do not smoke. Avoid pregnancy in severe PAH (high risk). Regular gentle walking as tolerated. Emotional stress management — stress hormones strain the pulmonary circulation.

Prognosis — What to Expect

Prognosis in pulmonary hypertension has improved dramatically over the past two decades. In the 1990s, median survival after a Group 1 PAH diagnosis was under 3 years. Today, with combination targeted therapies, many patients live 10 years or more after diagnosis. Group 4 patients who undergo successful surgery can achieve near-complete resolution of their pulmonary hypertension.

The key factors shaping prognosis are: how early the diagnosis was made, which WHO group the patient falls into, how well the right heart is still functioning at diagnosis, and how consistently the patient follows treatment. According to the European Pulmonary Hypertension Registry, and data published by AIIMS India, early diagnosis and referral to a specialist center are the strongest predictors of better outcomes.

Prevention & When to See a Doctor

Some forms of pulmonary hypertension — particularly genetic ones — cannot be completely prevented. But a great deal can be done to reduce your risk and catch the disease early before it causes serious damage.

Steps you can take to reduce risk:

If you have COPD, asthma, or sleep apnea — get it treated early and consistently
Control high blood pressure and diabetes — both damage blood vessels over time. If you are already on BP medication, read about why BP medicines must be continued even after BP normalizes
Avoid smoking completely — it accelerates lung vessel damage and worsens coronary artery disease
Keep LDL cholesterol under control — high cholesterol adds to vascular stress
Limit alcohol — chronic use stresses the heart and circulation
If you have had a pulmonary embolism (blood clot in the lungs), follow up carefully — Group 4 PH can develop months to years later. Watch for peripheral artery disease symptoms as well, which can coexist
If a family member has been diagnosed with PAH — get screened, even without symptoms. Also check for cardiomyopathy, which often runs in families alongside PAH
Monitor your resting heart rate regularly — abnormal rates can be an early signal. If your heart rate is unusually slow, read about bradycardia and its causes
At high altitudes, people with any cardiac or lung condition should consult a doctor before travel

See a doctor without delay if you notice: Breathlessness that is getting progressively worse over weeks, unexplained fatigue, dizziness on exertion, swelling in the legs, a persistent dry cough, or bluish discoloration of lips and fingertips. Do not wait for dramatic symptoms — in pulmonary hypertension, early evaluation genuinely changes outcomes. An echocardiogram is the first test your doctor will order, and it takes less than 30 minutes.

Frequently Asked Questions

Which WHO group of pulmonary hypertension is most common?

Group 2 — pulmonary hypertension due to left heart disease — is the most common overall. Group 1 (PAH) is the rarest but the most studied and the focus of most targeted drug therapies.

Can pulmonary hypertension be cured?

Group 4 (CTEPH) is the only form that can often be completely cured through surgery. Groups 1, 2, 3, and 5 are managed rather than cured — but with modern treatment, many patients live long, active lives.

Is pulmonary hypertension hereditary?

In Group 1 PAH, yes — up to 10–20 percent of cases have an identifiable genetic mutation (most commonly in the BMPR2 gene). If a family member has PAH, other members should be screened.

What test confirms pulmonary hypertension?

Right heart catheterization is the gold standard — it directly measures pulmonary artery pressure. An echocardiogram is used first as a screening test, but catheterization is needed for confirmation and classification.

Trusted Medical References

World Health Organization (WHO) — 2018 World Symposium on Pulmonary Hypertension Classification Guidelines
Mayo Clinic — Pulmonary Hypertension: Diagnosis and Treatment Protocols
Cleveland Clinic — Pulmonary Hypertension Patient Education Resources
MedlinePlus / U.S. National Institutes of Health (NIH) — Pulmonary Hypertension Overview
Johns Hopkins Medicine — Pulmonary Hypertension Research and Clinical Data
AIIMS India (All India Institute of Medical Sciences) — Cardiology Department Clinical Protocols
Indian Council of Medical Research (ICMR) — Cardiovascular Disease Burden in India
International Society for Heart and Lung Transplantation (ISHLT) — PH Treatment Guidelines
European Pulmonary Hypertension Registry — Long-term Survival Data
Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine — Pulmonary Hypertension Chapter
Rapid Interpretation of EKGs — Dale Dubin — Right Heart Strain Patterns in PH
Hurst's The Heart — Echocardiographic Evaluation in Pulmonary Hypertension
Dr. Vallerie McLaughlin, University of Michigan — Combination Therapy in PAH
Dr. William Auger, UC San Diego — Pulmonary Endarterectomy for CTEPH

Search This Blog

Realmedvision.com

Pulmonary Hypertension: WHO Classification, Symptoms, Causes & Treatment